BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression

Yanjie Kong(Shenzhen Second People's Hospital), Ceshi Chen(Army Medical University), Huang Haihui(Shenzhen Second People's Hospital), Chengang Zhou(Kunming Institute of Zoology), Meng Zhang(Shanxi University), Dewei Jiang(Kunming Institute of Zoology), Xia Liu(Northwestern University), Wenjing Liu(Kunming University of Science and Technology), Gong Chen(Guangdong Pharmaceutical University), Chang Cai(Shenzhen Second People's Hospital), Wenfeng Peng(Shenzhen Second People's Hospital), Xiuyun Sun(Tsinghua University), Hailin Zhang(Wenzhou Medical University), Wenxin Lv(Tsinghua University), Yu Rao(Soochow University), Chuanyu Yang(Kunming Institute of Zoology), Xin Weng(Shenzhen Second People's Hospital), Luzhen Wang(Nanjing Forestry University), Tianlong Lan(Tsinghua University)
Oncogene
August 20, 2024
10.1038/s41388-024-03121-1
Cited by 20

Related Papers

PROTACs: great opportunities for academia and industry
|Signal Transduction and Targeted Therapy|2019|627
Crystal structure of a bacterial homologue of glucose transporters GLUT1–4
|Nature|2012|488
PROTAC Technology: Opportunities and Challenges
|ACS Medicinal Chemistry Letters|2020|353
Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease
|Nature Communications|2015|280
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
|Cell Research|2018|280